中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
2期
189-190
,共2页
瞿章书%张炜%汤丽娟%何莉%徐小平
瞿章書%張煒%湯麗娟%何莉%徐小平
구장서%장위%탕려연%하리%서소평
乙型肝炎%山莨菪碱%治疗结果
乙型肝炎%山莨菪堿%治療結果
을형간염%산랑탕감%치료결과
Hepatitis B%Anisodamine%Treatment outcome
目的 研究山莨菪碱辅助治疗慢性乙型重型肝炎的临床疗效.方法 将150例慢性乙型重型肝炎患者按抽签法随机分为对照组和治疗组,各75例.对照组入院后接受拉米夫定100 mg/d抗病毒治疗及给予常规护肝,同时强调基础治疗及积极补充鲜血浆、白蛋白等综合治疗,有并发症者给予相应处理,有条件者常规接受人工肝血浆置换治疗1～3次,治疗组在此治疗基础上加用山莨菪碱20 mg/d静脉滴注或分2次静脉注射,对比2组患者病死率以及治疗前和治疗后2、4及8周血清总胆红素(TBiL)、ALT、凝血酶原时间(PT)等血清学指标的变化.结果 治疗8周后对照组好转42例(56.0%),无效33例(44.0%),死亡30例(40.0%);治疗组好转54例(72.0%),无效21例(28.0%),死亡18例(24.0%).治疗组好转率优于对照组(x2=4.17,P=0.041),病死率低于对照组(x2=4.41,P=0.036).2组存活患者(治疗组57例,对照组45例)治疗后肝功能均逐渐恢复,但治疗组血清肝功能指标下降迅速.结论 山莨菪碱辅助治疗慢性重型乙型肝炎有助于快速恢复肝功能、减低病死率.
目的 研究山莨菪堿輔助治療慢性乙型重型肝炎的臨床療效.方法 將150例慢性乙型重型肝炎患者按抽籤法隨機分為對照組和治療組,各75例.對照組入院後接受拉米伕定100 mg/d抗病毒治療及給予常規護肝,同時彊調基礎治療及積極補充鮮血漿、白蛋白等綜閤治療,有併髮癥者給予相應處理,有條件者常規接受人工肝血漿置換治療1～3次,治療組在此治療基礎上加用山莨菪堿20 mg/d靜脈滴註或分2次靜脈註射,對比2組患者病死率以及治療前和治療後2、4及8週血清總膽紅素(TBiL)、ALT、凝血酶原時間(PT)等血清學指標的變化.結果 治療8週後對照組好轉42例(56.0%),無效33例(44.0%),死亡30例(40.0%);治療組好轉54例(72.0%),無效21例(28.0%),死亡18例(24.0%).治療組好轉率優于對照組(x2=4.17,P=0.041),病死率低于對照組(x2=4.41,P=0.036).2組存活患者(治療組57例,對照組45例)治療後肝功能均逐漸恢複,但治療組血清肝功能指標下降迅速.結論 山莨菪堿輔助治療慢性重型乙型肝炎有助于快速恢複肝功能、減低病死率.
목적 연구산랑탕감보조치료만성을형중형간염적림상료효.방법 장150례만성을형중형간염환자안추첨법수궤분위대조조화치료조,각75례.대조조입원후접수랍미부정100 mg/d항병독치료급급여상규호간,동시강조기출치료급적겁보충선혈장、백단백등종합치료,유병발증자급여상응처리,유조건자상규접수인공간혈장치환치료1～3차,치료조재차치료기출상가용산랑탕감20 mg/d정맥적주혹분2차정맥주사,대비2조환자병사솔이급치료전화치료후2、4급8주혈청총담홍소(TBiL)、ALT、응혈매원시간(PT)등혈청학지표적변화.결과 치료8주후대조조호전42례(56.0%),무효33례(44.0%),사망30례(40.0%);치료조호전54례(72.0%),무효21례(28.0%),사망18례(24.0%).치료조호전솔우우대조조(x2=4.17,P=0.041),병사솔저우대조조(x2=4.41,P=0.036).2조존활환자(치료조57례,대조조45례)치료후간공능균축점회복,단치료조혈청간공능지표하강신속.결론 산랑탕감보조치료만성중형을형간염유조우쾌속회복간공능、감저병사솔.
Objective To study the clinical efficacy of anisodamine as adjuvant therapy of chronic severe hepatitis B. Methods One hundred and fifty cases of chronic severe hepatitis B were randomly divided into control group (75cases) and treated group (75cases). The control group were given lamivudine 100 mg/d and conventional treatment. Meanwhile some patients accepted 1-3 times of the treatment of Plasma Exchange. Besides the treatment in control group,the treated group had anisodamine (20 mg every day by intravenous drip or injection 2 times every day). The mortality rate and the changes of serum (such as TBIL,ALT,etc)of two groups before treatment and two weeks,4 weeks,8 weeks after treatment were compared. Results The mortality rate of treatment group decreased significantly(18/75),compared with control group(30/75)(x2=4.41,P＜0.05). The liver function of survival cases in both two groups (57 cases of treatment group,45cases of control group)was restored gradually. But the serum indicators of liver function of the treatment group decreased more rapidly that those in control group at 2 weeks,4 weeks and 8 weeks after treatment(P＜0.01). Conclusion Anisodamine can restore the liver function and reduce mortality in the treatment of chronic severe hepatitis B.
